Eli
Solbinsiran Demonstrates Significant Lipid Reductions in Phase 2 Trial for Mixed Dyslipidemia
Solbinsiran, siRNA, mixed dyslipidemia, Eli Lilly, PROLONG-ANG3, apolipoprotein B, LDL-C, triglycerides
Eli Lilly Partners with Magnet Biomedicine in $1.25B Molecular Glue Deal
Eli Lilly, Magnet Biomedicine, molecular glue, drug discovery, oncology, collaboration
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
Eli Lilly makes Zepbound vials cheaper for self-paying patients
self-paying, Eli, Eli Lilly, Prices, Monthly (qualifier value), Dosage, 7.5 mg, 10 mg
Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships
Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations
Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies
Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment
Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall
Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance
Hospital Group Seeks to Intervene in Lawsuit Against Lilly’s 340B Rebate Model
340B Drug Pricing Program, Eli Lilly, rebate model, lawsuit, hospital intervention, Health Resources and Services Administration (HRSA), drug pricing
Eli Lilly Streamlines Pipeline, Removing Alzheimer’s and Obesity Candidates in Q4 2024
Eli Lilly, pipeline update, Alzheimer’s disease, obesity, ceperognastat, clinical trials, drug development
Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer
Kailera Therapeutics, Jamie Coleman, Chief Commercial Officer, Obesity Treatment, Zepbound, Eli Lilly